General Information of Drug (ID: DMGNRZU)

Drug Name
PMID27376512-Compound-MTC-424 Drug Info
Cross-matching ID
TTD Drug ID
DMGNRZU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [1]
PMID27376512-Compound-Figure2aExample1 DMP59OX N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CN DMP7DL6 N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CG DMZIKN6 N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CM DMIS4H0 N. A. N. A. Patented [1]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [1]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [2]
NSC-622444 DMM5UT9 Discovery agent N.A. Investigative [2]
NSC-138419 DMH684Q Discovery agent N.A. Investigative [2]
NSC-319745 DMF3G06 Discovery agent N.A. Investigative [2]
NSC-348926 DM3TDEO Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CC-486 DMTNQB0 Acute myeloid leukaemia 2A60 Phase 3 [4]
S-110 DMXY34J Acute myeloid leukaemia 2A60 Phase 3 [5]
SGI110 DM1NQDW Acute myeloid leukaemia 2A60 Phase 3 [6]
Guadecitabine DM9Y3EG Myelodysplastic syndrome 2A37 Phase 3 [7]
Palifosfamide DMMIYZ7 Soft tissue sarcoma 2B57 Phase 2 [8]
RX-3117 DME8ARP Bladder cancer 2C94 Phase 2 [9]
Antroquinonol DMRGQVZ Non-small-cell lung cancer 2C25.Y Phase 2 [10]
GSK4172239 DM930LE Sickle-cell disorder 3A51 Phase 1 [11]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1) TT6S2FE DNMT1_HUMAN Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3A (DNMT3A) TTJUALD DNM3A_HUMAN Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B) TT6VZ78 DNM3B_HUMAN Inhibitor [1]

References

1 DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
2 Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
3 Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
4 Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
5 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
6 Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
9 Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
10 Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline